Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Galecto, Inc. is a clinical-stage biotech developing small molecule therapeutics targeting fibrosis, cancer, and liver diseases. Its core products include GB3226, an AML inhibitor, and GB1211, a galectin-3 inhibitor for oncology and liver conditions. The company focuses on high unmet medical needs, leveraging its expertise in galectin biology to improve treatment options and enhance immunotherapy efficacy.
This description was generated via AI from an annual report. Updated about 1 year ago.